JP2007509965A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007509965A5 JP2007509965A5 JP2006538281A JP2006538281A JP2007509965A5 JP 2007509965 A5 JP2007509965 A5 JP 2007509965A5 JP 2006538281 A JP2006538281 A JP 2006538281A JP 2006538281 A JP2006538281 A JP 2006538281A JP 2007509965 A5 JP2007509965 A5 JP 2007509965A5
- Authority
- JP
- Japan
- Prior art keywords
- dosage form
- unit dosage
- agonist
- niacin
- inflammatory drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 12
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 12
- 239000007892 solid unit dosage form Substances 0.000 claims 12
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims 11
- 229960003512 nicotinic acid Drugs 0.000 claims 11
- 235000001968 nicotinic acid Nutrition 0.000 claims 11
- 239000011664 nicotinic acid Substances 0.000 claims 11
- 238000000034 method Methods 0.000 claims 10
- 229940084820 Peroxisome proliferator-activated receptor alpha agonist Drugs 0.000 claims 6
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims 5
- 229940080774 Peroxisome proliferator-activated receptor gamma agonist Drugs 0.000 claims 5
- 229960001138 acetylsalicylic acid Drugs 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 4
- 239000002356 single layer Substances 0.000 claims 4
- 230000001965 increasing effect Effects 0.000 claims 3
- WSYRBHQWMXTCHQ-SFIKJRKMSA-N (2s)-n-[(2r)-1-[[(2s)-1-[[(2r)-1-[[(2r)-1-[[(2s)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]amino]-3-(1h-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(1h-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1h-indol-3-yl)-1-oxopropan-2-yl]-2-[[( Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C1=CC=CC=C1 WSYRBHQWMXTCHQ-SFIKJRKMSA-N 0.000 claims 2
- 210000001789 adipocyte Anatomy 0.000 claims 2
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 claims 2
- 229960002297 fenofibrate Drugs 0.000 claims 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims 2
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 claims 2
- 230000002195 synergetic effect Effects 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 claims 1
- 229940123208 Biguanide Drugs 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 1
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 238000011010 flushing procedure Methods 0.000 claims 1
- 229960001680 ibuprofen Drugs 0.000 claims 1
- 229960000905 indomethacin Drugs 0.000 claims 1
- 229960002009 naproxen Drugs 0.000 claims 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229960002895 phenylbutazone Drugs 0.000 claims 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 claims 1
- 229960005095 pioglitazone Drugs 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51589103P | 2003-10-29 | 2003-10-29 | |
| PCT/US2004/035910 WO2005041878A2 (en) | 2003-10-29 | 2004-10-29 | Compositions and methods for increasing hdl and hdl-2b levels |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007509965A JP2007509965A (ja) | 2007-04-19 |
| JP2007509965A5 true JP2007509965A5 (OSRAM) | 2007-12-13 |
Family
ID=34549456
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006538281A Pending JP2007509965A (ja) | 2003-10-29 | 2004-10-29 | Ｈｄｌ及びｈｄｌ−２ｂレベルを高めるための組成物及び方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20050148556A1 (OSRAM) |
| EP (1) | EP1684704A2 (OSRAM) |
| JP (1) | JP2007509965A (OSRAM) |
| CA (1) | CA2543170A1 (OSRAM) |
| TW (1) | TW200624125A (OSRAM) |
| WO (1) | WO2005041878A2 (OSRAM) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7094572B2 (en) | 2003-03-14 | 2006-08-22 | Bristol-Myers Squibb | Polynucleotide encoding a novel human G-protein coupled receptor variant of HM74, HGPRBMY74 |
| US20080058292A1 (en) * | 2003-10-29 | 2008-03-06 | Raif Tawakol | Method for increasing HDL and HDL-2b levels |
| US20090069275A1 (en) * | 2006-02-17 | 2009-03-12 | Rocca Jose G | Low flush niacin formulation |
| US8008328B2 (en) * | 2007-01-23 | 2011-08-30 | Reddy Us Therapeutics, Inc. | Methods for the treatment of diabetes-associated dyslipdemia |
| WO2008100249A1 (en) * | 2007-02-13 | 2008-08-21 | Kos Life Sciences, Inc. | Low flush niacin formulation |
| US8404275B2 (en) * | 2007-07-01 | 2013-03-26 | Vitalis Llc | Combination tablet with chewable outer layer |
| US20170042821A1 (en) * | 2007-07-01 | 2017-02-16 | Vitalis Llc | Combination tablet with chewable outer layer |
| WO2009033078A2 (en) * | 2007-09-05 | 2009-03-12 | Raif Tawakol | Compositions and methods for controlling cholesterol levels |
| AU2009249600A1 (en) * | 2008-05-20 | 2009-11-26 | Cerenis Therapeutics Holding S.A. | Niacin and NSAID for combination therapy |
| MX2010013169A (es) * | 2008-06-02 | 2010-12-21 | Reddy S Lab Ltd | Formulaciones de niacina de liberacion modificada. |
| US20110086074A1 (en) * | 2008-06-02 | 2011-04-14 | Dr. Reddy's Laboratories Ltd. | Combinations of niacin and an oxicam |
| US9226891B2 (en) | 2011-10-28 | 2016-01-05 | Vitalis Llc | Anti-flush compositions |
| WO2014159684A1 (en) * | 2013-03-13 | 2014-10-02 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treating or preventing insulin resistance or abnormal levels of circulating lipids in a mammal |
| US10695309B2 (en) * | 2017-03-31 | 2020-06-30 | Western New England University | Sustained-release liothyronine formulations, method of preparation and method of use thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3312593A (en) * | 1965-03-10 | 1967-04-04 | Carter Prod Inc | Anti-inflammatory compositions of aspirin and niacin |
| US4080472A (en) * | 1974-03-22 | 1978-03-21 | Societe D'etudes Et D'exploitation De Marques Et Brevets S.E.M.S. | Metformin 2-(p-chlorophenoxy)-2-methylpropionate |
| CA2218696A1 (en) * | 1995-04-19 | 1996-10-24 | L. Jackson Ii Roberts | Compositions, kits and methods for administration of antilipemic and an ti-platelet aggregation drugs |
| DE69841395D1 (de) * | 1997-07-31 | 2010-01-28 | Abbott Respiratory Llc | Zusammensetzung enthaltend einen HMG-CoA-Reduktasehemmer und eine Nikotinsäureverbindung zur Behandlung von Hyperlipidämie |
| US6469035B1 (en) * | 1997-07-31 | 2002-10-22 | Eugenio A. Cefali | Methods of pretreating hyperlipidemic individuals with a flush inhibiting agent prior to the start of single daily dose nicotinic acid therapy to reduce flushing provoked by nicotinic acid |
| US20010006644A1 (en) * | 1997-07-31 | 2001-07-05 | David J. Bova | Combinations of hmg-coa reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia once a day at night |
| US6121249A (en) * | 1998-07-01 | 2000-09-19 | Donald L. Weissman | Treatment and prevention of cardiovascular diseases with help of aspirin, antioxidants, niacin, and certain B vitamins |
| US7323496B2 (en) * | 1999-11-08 | 2008-01-29 | Theracos, Inc. | Compounds for treatment of inflammation, diabetes and related disorders |
| AU2001288294A1 (en) * | 2000-08-21 | 2002-03-04 | Merck And Co., Inc. | Anti-hypercholesterolemic drug combination |
| AU2001292874B2 (en) * | 2000-09-27 | 2006-06-15 | Merck & Co., Inc. | Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders |
| HUP0500543A2 (hu) * | 2000-11-20 | 2005-09-28 | Bristol-Myers Squibb Company | Piridonszármazékok mint aP2 inhibitorok és a vegyületeket tartalmazó gyógyszerkészítmények |
-
2004
- 2004-10-29 WO PCT/US2004/035910 patent/WO2005041878A2/en not_active Ceased
- 2004-10-29 EP EP04817473A patent/EP1684704A2/en not_active Withdrawn
- 2004-10-29 JP JP2006538281A patent/JP2007509965A/ja active Pending
- 2004-10-29 CA CA002543170A patent/CA2543170A1/en not_active Abandoned
- 2004-10-29 US US10/977,508 patent/US20050148556A1/en not_active Abandoned
-
2005
- 2005-01-11 TW TW094100736A patent/TW200624125A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2485942C2 (ru) | Бупропиона гидробромид и его терапевтические применения | |
| JP5241228B2 (ja) | 非ステロイド性抗炎症薬、鬱血除去薬および鎮静作用の少ない抗ヒスタミン薬を含む多層錠 | |
| JP5202522B2 (ja) | 制御性放出製剤および関連する方法 | |
| RU2007126652A (ru) | Композиции и способы стабилизации активных фармацевтических ингредиентов | |
| JP2009543885A5 (OSRAM) | ||
| JPWO2009151116A1 (ja) | 非アルコール性脂肪肝炎の予防／改善・治療薬 | |
| JP2005508371A5 (OSRAM) | ||
| EP2011487A3 (en) | Pharmaceutical compositions for gastroinetestinal drug delivery | |
| JP2015503583A5 (OSRAM) | ||
| DE602007013380D1 (de) | Pharmazeutische kombination mit 3- (3-dimethylamino-1-ethyl-2-methyl-propyl) phenol und einem nsar | |
| JP2009526087A5 (OSRAM) | ||
| WO2007112274A3 (en) | Formulations of low dose non-steroidal anti-inflammatory drugs and beta-cyclodextrin | |
| JP2008543936A5 (OSRAM) | ||
| JP2009508960A5 (OSRAM) | ||
| RU2008151946A (ru) | Фармацевтические композиции для пролонгированного высвобождения фенилэфрина | |
| RU2005108609A (ru) | Лекарственные формы с модифицированным высвобождением, имеющие два ядра и отверстие | |
| JP2005097255A5 (OSRAM) | ||
| JP2012505830A5 (OSRAM) | ||
| JP2009508916A5 (OSRAM) | ||
| CN1874754A (zh) | 控释镇痛悬浮液 | |
| CA2778825C (en) | Treatment of sunburn using analgesics and antihistamines | |
| Gumbrevičius et al. | Paracetamol and simvastatin: a potential interaction resulting in hepatotoxicity | |
| EA200701681A1 (ru) | Пероральная лекарственная форма, содержащая росиглитазон | |
| DE602004009113D1 (de) | Antimykobakterielle pharmazeutische zusammensetzung mit einem arzneimittel gegen tuberkulose | |
| JP2009506044A5 (OSRAM) |